Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
AssigneesPfizer Inc., Astellas Pharma Inc.
InventorsAkos Gabor Czibere, Dana Ann Kennedy
Life of this patent
Estimating the term…
Abstract
This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses for the treatment of metastatic castration-sensitive prostate cancer in subjects identified as having at least one DNA damage repair gene mutation.
Claims20
A method of treating metastatic castration-sensitive prostate cancer in a subject in need thereof, wherein the subject has been identified as having at least one DNA damage repair gene mutation, comprising administering to the subject a combination therapy which comprises talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof.
A method of treating metastatic castration-sensitive prostate cancer in a subject in need thereof, comprising a) detecting at least one DNA damage repair gene mutation from a biopsy of the metastatic cancer or a peripheral blood sample from the subject;
- and b) administering to the subject a combination therapy which comprises talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof.
The method of any of the proceeding claims, wherein the subject is a human.
Dependencies are inferred from the claim text.